Clinical Trial Update: Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of an anti-PD-1 antibody with chemotherapy in metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED